Eloxx: Independent Confirmation of Positive Biopsy Results in All Patients in Phase 2 Alport Study

 Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans

All three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacement post-treatment in kidney biopsies demonstrating the disease modifying effect of ELX-02

Podocyte foot process effacement is a hallmark of Alport syndrome

Eloxx intends to gain alignment with U.S. Food and Drug Administration (FDA) on design of pivotal trial and potential for seeking Breakthrough Therapy Designation

https://finance.yahoo.com/news/eloxx-pharmaceuticals-reports-independent-confirmation-110000183.html